Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension

Iranian Journal of Pediatrics

Volumn 27, Issue 1, 2017, Pages

  Alipour, Mohammad Reza ^a   Lookzadeh, Mohammad Hossein ^a   Namayandeh, Seyedeh Mahdieh ^a   Pezeshkpour, Zohreh ^a   Sarebanhassanabadi, Mohammadtaghi ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Persistent pulmonary hypertension; Sildenafil; Tadalafil

Indexed keywords

SILDENAFIL; TADALAFIL;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; LUNG ARTERY PRESSURE; NEWBORN; PULMONARY HYPERTENSION; SINGLE DRUG DOSE; TRICUSPID VALVE REGURGITATION;

EID: 85014639789     PISSN: 20082142     EISSN: 20082150     Source Type: Journal    
DOI: 10.5812/ijp.6385     Document Type: Article

References (31)

1. Oishi P, Datar SA, Fineman JR. Advances in the management of pediatric pulmonary hypertension. Respir Care. 2011;56(9):1314–39. doi: 10.4187/respcare.01297.
2. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med. 2010;11(2 Suppl):S79–84. doi: 10.1097/PCC.0b013e3181c76cdc.
3. Teixeira-Mendonca C, Henriques-Coelho T. Pathophysiology of pulmonary hypertension in newborns: therapeutic indications. Rev Port Cardiol. 2013;32(12):1005–12. doi: 10.1016/j.repc.2013.06.010.
4. Morin FC, Stenmark KR. Persistent pulmonary hypertension of the newborn. Am J Respirat Crit Care Med. 1995;151(6):2010–32.
5. Derleth DP. Treatment of persistent pulmonary hypertension in the neonate. J pediatr. 1992;120(6):1004.
6. Delsing B, Lopriore E, Blom N, Te Pas AB, Vandenbussche FP, Walther FJ. Risk of persistent pulmonary hypertension of the neonate in twin-to-twin transfusion syndrome. Neonatology. 2007;92(2):134–8. doi: 10.1159/000101433.
7. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–537. doi: 10.1093/eurheartj/ehp297.
8. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S78–84. doi: 10.1016/j.jacc.2009.04.017.
9. Ivy DD, Feinstein JA, Humpl T, Rosenzweig EB. Non-scongenital heart disease associated pediatric pulmonary arterial hypertension. Prog Pediatr Cardiol. 2009;27(1-2):13–23. doi: 10.1016/j.ppedcard.2009.09.004.
10. Kumar VH, Swartz DD, Rashid N, Lakshminrusimha S, Ma C, Ryan RM, et al. Prostacyclin and milrinone by aerosolization improve Pulmonary hemodynamics in newborn lambs with experimental Pulmonary hypertension. J Appl Physiol (1985). 2010;109(3):677–84. doi: 10.1152/japplphysiol.01082.2009.
11. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr. 2002;141(6):830–2. doi: 10.1067/mpd.2002.129849.
12. Lakshminrusimha S, Porta NF, Farrow KN, Chen B, Gugino SF, Kumar VH, et al. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med. 2009;10(1):106–12. doi: 10.1097/PCC.0b013e3181936aee.
13. McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med. 2013;14(1):74–84. doi: 10.1097/PCC.0b013e31824ea2cd.
14. Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J Perinatol. 2008;28 Suppl 3:S67–71. doi: 10.1038/jp.2008.158.
15. Steinhorn RH. Therapeutic approaches using nitric oxide in infants and children. Free Radic Biol Med. 2011;51(5):1027–34. doi: 10.1016/j.freeradbiomed.2011.01.006.
16. Latus H, Delhaas T, Schranz D, Apitz C. Treatment of pulmonary arterial hypertension in children. Nat Rev Cardiol. 2015;12(4):244–54. doi: 10.1038/nrcardio.2015.6.
17. Pan D, Rubin GM. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell. 1997;90(2):271–80.
18. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–92.
19. Hori Y, Kondo C, Matsui M, Yamagishi M, Okano S, Chikazawa S, et al. Effect of the phosphodiesterase type 5 inhibitor tadalafil on Pulmonary hemodynamics in a canine model of pulmonary hypertension. Vet J. 2014;202(2):334–9. doi: 10.1016/j.tvjl.2014.08.009.
20. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488–520. doi: 10.1124/pr.58.3.5.
21. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83(5A):13C–20C.
22. Madhani M, Okorie M, Hobbs AJ, MacAllister RJ. Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo. Br J Pharmacol. 2006;149(6):797–801. doi: 10.1038/sj.bjp.0706920.
23. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest. 2006;129(2):417–25. doi: 10.1378/chest.129.2.417.
24. Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, et al. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(8):861–9. doi: 10.1164/rccm.200801-121OC.
25. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57. doi: 10.1056/NEJMoa050010.
26. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903. doi: 10.1161/CIRCULATIONAHA.108.839274.
27. Sabri MR, Beheshtian E. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with Pulmonary arterial hypertension. Pediatr Cardiol. 2014;35(4):699–704. doi: 10.1007/s00246-013-0840-z.
28. Lichtblau M, Harzheim D, Ehlken N, Marra A, Pinado FP, Grunig E, et al. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. Lung. 2015;193(1):105–12. doi: 10.1007/s00408-014-9657-7.
29. Shiva A, Shiran M, Rafati M, Zamani H, Babazadeh K, Saeedi M, et al. Oral Tadalafil in Children with Pulmonary Arterial Hypertension. Drug Res (Stuttg). 2016;66(1):7–10. doi: 10.1055/s-0034-1395510.
30. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012;33(5):683–8. doi: 10.1007/s00246-012-0180-4.
31. Tessler RB, Zadinello M, Fiori H, Colvero M, Belik J, Fiori RM. Tadalafil improves oxygenation in a model of newborn Pulmonary hypertension. Pediatr Crit Care Med. 2008;9(3):330–2. doi: 10.1097/PCC.0b013e31816c7035.